As companies seek new ways to address the rising threat of treatment-resistant Candida auris infections, they are calling for additional development incentives, such as R&D tax credits, that can spur investment in the space.
During a panel at the 2017 BIO International Convention, Tom Chiller, associate director for epidemiologic science at the Centers for Disease Control & Intervention, reported that Candida auris pathogens are a leading cause of blood infections worldwide and are on the rise in the US